DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

Information source: Peking University First Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Vascular Dementia; Stroke

Intervention: Cilostazol (Drug); Aspirin (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Peking University First Hospital

Official(s) and/or principal investigator(s):
Huang Yining, MD PhD, Principal Investigator, Affiliation: Peking University First Hospital


The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.

Clinical Details

Official title: Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: changes of the scores of MMSE, MOCA,CDR,and Blessed-Roth

Secondary outcome: stroke recurrence, other vascular ischemic events, bleeding events


Minimum age: 40 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria: 1. Age ranging from 40 to 80 years 2. After newly ischemic stroke from 3 months to 2 years 3. Brain CT or MRI shows stroke lesions and white matter lesions, ARWMC(Age Related White Matter Change)>=4 4. Moderate or mild cognitive deficits: MMSE 12-26 5. Vascular or mixed dementia: Hachinski ischemic score>4 6. Moderate or mild disability: MRS<=4,NIHSS<20 7. Informed consent Exclusion Criteria: 1. Definitive diagnosis of dementia prior to the stroke 2. Cerebral hemorrhage in the past 3. Cerebral embolism result from cardiogenic embolus 4. Critically ills: MRS>4,NIHSS>=20 5. Bed-ridden patient who is hardly discovered newly stroke 6. patient with sever cardiac, hepatic or nephric complication 7. dementia caused not by vascular lesions 8. other diseases disturb the cognitive evaluation 9. susceptibility to varieties of allergen 10. abstain from Cilostazol or Asprin 11. antiplatelet treatment, anticoagulation or fibrinolysis are needed because of other diseases 12. rejected to participate by the patient or the family

Locations and Contacts

Peking University First Hospital, Beijing, Beijing 100034, China

Shanghai Hua Shan Hospital, Shanghai, Shanghai 200040, China

Additional Information

Starting date: March 2008
Last updated: May 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017